Tech Company Financing Transactions

Adela Funding Round

Adela, operating out of Los Angeles, secured $48 million in funding from Decheng Capital, Deerfield Management Company and F-Prime Capital.

Transaction Overview

Company Name
Announced On
9/26/2023
Transaction Type
Venture Equity
Amount
$48,000,000
Round
Undisclosed
Proceeds Purpose
The company intends to use the funds to advance its technology platform and commercialize its first product for MRD monitoring, while further developing a multi-cancer early detection (MCED) product.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
9595 Wilshire Blvd.
Los Angeles, CA 90212
USA
Phone
Undisclosed
Email Address
Overview
Adela's mission is to develop innovative and accessible technologies that harness biology and change the way we diagnose and treat disease. Adela's genome-wide methylation enrichment technology was originally developed by Chief Scientific Officer Dr. Daniel De Carvalho, PhD, at University Health Network's Princess Margaret Cancer Centre.
Profile
Adela LinkedIn Company Profile
Social Media
Adela Company Twitter Account
Company News
Adela News
Facebook
Adela on Facebook
YouTube
Adela on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Scott Bratman
  Scott Bratman LinkedIn Profile  Scott Bratman Twitter Account  Scott Bratman News  Scott Bratman on Facebook
Chief Medical Officer
Anne-Renee Hartman
  Anne-Renee Hartman LinkedIn Profile  Anne-Renee Hartman Twitter Account  Anne-Renee Hartman News  Anne-Renee Hartman on Facebook
Chief Operating Officer
Todd Arnold
  Todd Arnold LinkedIn Profile  Todd Arnold Twitter Account  Todd Arnold News  Todd Arnold on Facebook
Chief Scientific Officer
Daniel De Carvalho
  Daniel De Carvalho LinkedIn Profile  Daniel De Carvalho Twitter Account  Daniel De Carvalho News  Daniel De Carvalho on Facebook
Controller
Priscilla Huang
  Priscilla Huang LinkedIn Profile  Priscilla Huang Twitter Account  Priscilla Huang News  Priscilla Huang on Facebook
VP - General Counsel
Karla Jarvis
  Karla Jarvis LinkedIn Profile  Karla Jarvis Twitter Account  Karla Jarvis News  Karla Jarvis on Facebook


 

 

Browse more venture capital transactions:

Prev: 9/26/2023: Atinary Technologies venture capital transaction
Next: 9/27/2023: Avalyn Pharma venture capital transaction

 

Share this article

 


About Our VC Transactions Data

We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary